ENANTIOMERIC COMPOSITIONS OF CICLETANINE, IN COMBINATION WITH OTHER AGENTS, FOR THE TREATMENT OF HYPERTENSION

摘要

Embodiments of the invention include formulations and methods of use of furopyridine-based compositions alone and in combination with one or more various second therapeutic agents for the treatment of disease in human subjects. The furopyridine composition may include one or more furopyridine species, of which cicletanine as an example. The furopyridines may take various enantiomeric forms. Cicletanine, for example, may be present as (1) pure (+) enantiomer, (2) a non racemic mixture in which the (+) enantiomer is the major form and the (-) enantiomer is the minor form, (3) a racemic mixture in which the (+) and (-) enantiomers are equally present, (4) a non-racemic mixture in which the (-) enantiomer is the major form and the (+) enantiomer is the minor form, and (5) the pure (-) enantiomer. Second agents included in embodiments of the invention may be any drug that is useful in combination with a furopyridine composition in the treatment of disease. Such diseases may include, for example, heart disease, vascular disease, hypertension, diabetes, metabolic syndrome, polycystic ovarian syndrome, and autoimmune disorders. Some of these diseases commonly are associated with endothelial dysfunction and imbalances of imbalances of prostacyclin or of reactive oxygen species (ROS) or reactive nitrogen species (RNS). Second agents may include, for example, antihypertensive agents, such as beta blockers, aldosterone blockers, calcium antagonists, and metal supplements. In terms of mechanism of action, such second agents may advantageously include agents that increase prostacyclin activity, inhibit phosphodiesterase, inhibit protein kinases, or increase insulin sensitivity.